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TWEAK (tumor necrosis factor–like weak inducer of apoptosis)
is a TNF superfamily cytokine that activates the fibroblast
growth factor–inducible 14 (Fn14) receptor. Transcriptional
analysis of experimental kidney tubulointerstitial
inflammation showed a correlation between an upregulation
of the mRNA for the transmembrane chemokine CXCL16, a
T-cell chemoattractant, and Fn14 activation. Exogenous
TWEAK increased mouse kidney CXCL16 expression and
T-lymphocyte infiltration in vivo, processes inhibited by the
NF-jB inhibitor parthenolide. Tubular cell CXCL16 was
increased in a nephrotoxic tubulointerstitial inflammation
model and neutralizing anti-TWEAK antibodies decreased
this CXCL16 expression and lymphocyte infiltration. In
human kidney biopsies with tubulointerstitial inflammation,
tubular cell CXCL16 and Fn14 expressions were associated
with inflammatory infiltrates. TWEAK upregulated CXCL16
mRNA expression in cultured renal tubular cells in an
NF-jB-dependent manner and increased soluble and
cellular CXCL16 protein. CXCL16 modestly promoted the
expression of cytokines in tubular cells expressing its
receptor (CXCR6) and appeared to synergize with
TWEAK to promote an inflammatory response; however, it
did not modulate tubular cell proliferation or survival.
Thus, TWEAK upregulates the expression of the chemokine
CXCL16 in tubular epithelium and this may contribute
to kidney tubulointerstitial inflammation.
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Tubulointerstitial inflammation (TII) is a key component
of both acute kidney injury and chronic kidney disease.
Chemokines promote kidney TII.1 Members of the tumor
necrosis factor (TNF) superfamily of cytokines regulate
several cell responses, including proliferation, differentiation,
cell death, and inflammation.2 Tumor necrosis factor–like
weak inducer of apoptosis (TWEAK, TNFSF12) is a TNF
superfamily member that regulates glomerular and tubu-
lointerstitial inflammatory responses,3–7 cell death, and cell
proliferation in a cell-type- and microenvironment-depen-
dent manner.4,5,8–11 TWEAK signals via the fibroblast growth
factor–inducible 14 (Fn14) receptor.3,5 TWEAK regulates the
expression of several chemokines, but the specific chemo-
kines vary with cell type and are subject to differential
regulation. In renal tubular cells, TWEAK promotes the
canonical nuclear factor-kB (NF-kB)-dependent secretion
of MCP-1/CCL2 and RANTES/CCL5, but also the non-
canonical NF-kB-dependent secretion of CCL19 and
CCL21.3,12 TWEAK also upregulates MIP-1a/CCL3 and
10 kDa interferon gamma-induced protein (IP-10)/CXCL10
in mesangial cells. However, TWEAK does not upregulate
MCP-1 in bronchial epithelium or keratinocytes.12–14
Most chemokines are released as soluble mediators.1
However, CX3CL1 (fractalkine) and CXCL16 (SR-PSOX)
are synthesized as transmembrane molecules and can be
cleaved from the cell surface to produce a soluble
chemoattractant.15 Fractalkine has been extensively studied
in the context of kidney disease.16 However, much less is
known about CXCL16 and kidney injury. CXCL16 was
originally described as a scavenger receptor for phosphati-
dylserine and oxidized low-density lipoprotein and termed
SR-PSOX.17 Independently, CXCL16 was identified as a
ligand for the CXC-chemokine receptor CXCR6.18 CXCL16 is
one of two known membrane-anchored chemokines, con-
sisting of an extracellular N-terminal chemokine domain,
glycosylated mucin-like stalk, transmembrane-spanning
region, and a short cytoplasmic tail.18–20 CXCL16 potentially
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functions as both a soluble chemokine and a membrane-
bound adhesion molecule.21,22 These peculiarities make a
complete understanding of CXCL16 regulation in kidney cells
of particular interest. Indeed, CXCL16 has been implicated in
renal disease. CXCL16 expression is increased in various
animal models of kidney injury and human nephro-
pathies.23–28 CXCL16 promotes progression of damage from
acute inflammation to a progressive phase of established
glomerulonephritis in rats.26 Interestingly, elevated levels of
urinary CXCL16 in patients with acute tubular necrosis23 or
lupus nephritis27 suggest that CXCL16 may be a potential
diagnostic biomarker in these kidney diseases. Despite
TWEAK being another potential urinary biomarker of lupus
nephritis, and a cytokine that regulates the expression of
several chemokines, no previous studies had addressed the
relationship between TWEAK and CXCL16. In addition,
there were no prior studies on factors that regulate CXCL16
expression in vivo in experimental nephropathy models, and
no actions of CXCL16 on renal tubular epithelium had been
previously characterized.
We have now studied TWEAK regulation of CXCL16
expression in vivo and in tubular cells in culture, as well as
CXCL16 function in these cells.
RESULTS
Transcriptomics analysis of chemokine mRNA expression in
murine TII
To search for novel molecular networks that may contribute
to kidney inflammation, the transcriptome of an inflammatory
murine model of kidney tubular injury induced by a folic acid
overdose3,29–31 was analyzed. Several chemokines, as well as
the TWEAK receptor Fn14, were upregulated (Supplementary
Table S1 online). There is an extensive understanding of
the role and regulation in kidney disease of many classical
chemokines.1,32 However, less is known about the trans-
membrane chemokines CX3CL1 and CXCL16, which were
also upregulated in this model. CX3CL1 involvement in folic
acid nephropathy has been previously addressed.33 CXCL16
expression closely correlated with Fn14 expression (Supple-
mentary Figure S1A online) and was studied in more detail.
TWEAK modulates renal CXCL16 expression and
T-lymphocyte infiltration in vivo
Systemic TWEAK administration increases CXCL16 mRNA
expression in healthy murine kidneys at 4 h (Figure 1a). This
was abrogated by the NF-kB inhibitor parthenolide, indicat-
ing NF-kB dependence. In vivo, CXCL16 has an important
role in the recruitment of T cells to sites of inflammation,23
and, recently, TWEAK was shown to induce kidney infiltra-
tion by T cells.34 In this regard, renal interstitial CD3-positive
lymphocytes increased 4 h post TWEAK injection, and
parthenolide decreased TWEAK-induced CD3-lymphocyte
infiltration (Figure 1b). Kidney CD3 infiltration persisted at
24 h (not shown). Immunohistochemistry localized CXCL16
expression to tubular epithelium in control kidneys and
kidneys from TWEAK-injected mice (Figure 2). Lectin
binding identified the distal nephron as the main source of
CXCL16 (Supplementary Figure S2 online). In addition,
proximal tubular cells near glomeruli and Bowman’s
capsule cells near the proximal tubule expressed CXCL16
(Supplementary Figure S2 online).
Neutralization of TWEAK reduces tubular CXCL16 expression
in kidney TII
Acute kidney injury and progressive loss of renal function are
associated with interstitial inflammation and tubular in-
jury.35 Tubular epithelial cells release cytokines in response to
various immune and nonimmune factors contributing to
attraction of inflammatory cells to the kidney.36 As TWEAK
modulates tubular CXCL16 in vivo, we studied in further
detail the relationship between TWEAK and kidney CXCL16
expression in an inflammatory model of tubular injury
induced by a folic acid overdose.3,29–31 We had previously
observed a key role for TWEAK in TII in this model, as
tubular cell TWEAK and Fn14 are increased (by 3.5- and
10-fold at 72 h) and TWEAK targeting by anti-TWEAK
antibodies decreased inflammation and preserved renal
function.3,37 We now report kidney CXCL16 and CXCR6
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Figure 1 |TWEAK (tumor necrosis factor–like weak inducer
of apoptosis) induces renal CXCL16 expression in vivo.
(a) Quantification of CXCL16 mRNA by real-time quantitative
reverse transcription-PCR in kidneys from mice 4 h after the
administration of TWEAK and/or parthenolide. *Po0.003 vs.
control. #Po0.05 vs. TWEAK. Data were normalized with murine
glyceraldehyde-3-phosphate dehydrogenase mRNA. (b)
Quantification of CD3-positive cells 4 h after TWEAK or/and
parthenolide injection. *Po0.009 vs. control. #Po0.01 vs. TWEAK.
Mean±s.e.m. of six animals per group. h.p.f, high power field.
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mRNA upregulation in this model (Figure 3). Blockade of
TWEAK by anti-TWEAK antibody prevented the increased
CXCL16 and CXCR6 mRNA expression, suggesting a role for
TWEAK in regulating CXCL16 expression during TII (Figure
3a and b). The histological evaluation showed tubulointer-
stitial injury in folic acid–injected mice, which was reduced by
TWEAK neutralization (Figure 3c). Immunohistochemistry
localized the increased CXCL16 expression to tubular cells
(Figure 4). CXCL16 expression was very prominent in the basolat-
eral tubular membrane of some tubules and luminal side of
others (Figure 4). In addition, interstitial CD3-positive lympho-
cytes were increased in untreated animals, and neutralization of
TWEAK decreased the number of CD3 lymphocytes (Figure 5).
Increased tubular CXCL16 and Fn14 expression in human TII
CXCL16 and Fn14 protein expression levels were studied in
human TII secondary to glomerular injury while minimal
change disease served as a control (Figure 6). In human TII,
CXCL16-positive tubules were found in close association
with inflammatory infiltrates (Figure 6a). These tubules also
expressed the TWEAK receptor, Fn14, and thus may be
activated by TWEAK from the local environment (Figure 6b).
These findings were observed in all the samples with tubulo-
interstitial cell infiltration. In addition, tubular expression of
both Fn14 and CXCL16 (control for the technique is shown
in Supplementary Figure S3 online) was observed in human
acute interstitial nephritis (Figure 7).
TWEAK upregulates CXCL16 expression in renal tubular cells
Consistent with the in vivo data, we examined the influence
of TWEAK on CXCL16 expression in cultured renal tubular
cells. In proximal tubular MCT cells, CXCL16 mRNA
expression was significantly increased from 3 to 24 h
following exposure to 100 ng/ml TWEAK (Figure 8a). In
tubular MCT cells, TWEAK activates the canonical NF-kB
pathway and this is prevented by parthenolide.3 Inhibition of
NF-kB activation by parthenolide prevented TWEAK-
induced CXCL16 upregulation (Figure 8b). Flow cytometry
showed increased cell surface CXCL16 after TWEAK
stimulation for 6–24 h (Figure 8c).
Distal tubular NP-1 cells constitutively released soluble
CXCL16 into the cell culture medium (Figure 8d). TWEAK
further potentiated the shedding of CXCL16 from renal
tubular cells and increased cellular CXCL16 (Figure 8d).
Confocal microscopy disclosed that TWEAK increased
cytoplasmic and membrane CXCL16 in both MCT (Figure
9a and b) and NP-1 cells (Figure 9c). Both cell types
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Figure 2 | Localization of TWEAK (tumor necrosis factor–like
weak inducer of apoptosis)-induced renal CXCL16 expression
in vivo. In control kidneys CXCL16 located mainly to tubules.
In TWEAK-injected animals, an increased number of CXCL16-
expressing tubules is noted. CXCL16 immunohistochemistry.
Original magnification  400. Pictures are representative of six
animals per group.
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Figure 3 |TWEAK (tumor necrosis factor–like weak inducer of
apoptosis) neutralization decreases CXCL16 and CXCR6 mRNA
expression in experimental tubulointerstitial inflammation
(TII). (a) During experimental TII, CXCL16 mRNA is increased.
TWEAK neutralization decreased kidney CXCL16 mRNA (real-time
quantitative reverse transcription-PCR (qRT-PCR)). *Po0.001 vs.
control, **Po0.01 vs. TII, #Po0.05 vs. TIIþ IgG. Data were
normalized with 18s eukaryotic ribosomal RNA. (b) During
experimental TII, CXCR6 mRNA is increased. TWEAK neutralization
decreased kidney CXCR6 mRNA (real-time qRT-PCR). *Po0.01 vs.
control, **Po0.03 vs. TII. Data were normalized with 18s
eukaryotic ribosomal RNA. (c) Histological assessment confirmed
that cellular tubulointerstitial injury was decreased by anti-TWEAK
antibodies. *Po 0.001 vs. control, **Po0.003 vs. TII, #Po0.003 vs.
TIIþ IgG. Mean±s.e.m. of eight animals per group.
1100 Kidney International (2012) 81, 1098–1107
or ig ina l a r t i c l e MC Izquierdo et al.: TWEAK, CXCL16, and inflammation
expressed the CXCL16 receptor, CXCR6 (Figure 9a–c).
CXCL16 and CXCR6 were found in close association at the
cell membrane in some cells (Figure 9b).
CXCL16 modulates the inflammatory response in
tubular cells
TWEAK induces proliferation in nonstimulated tubular
MCT cells, but the cell microenvironment modulates this
response and certain inflammatory cytokines, such as TNF-a
and interferon (IFN)-g, change the response to apoptosis.4
We confirmed that TWEAK did not promote tubular cell
apoptosis but induced tubular cell proliferation34,37 (Figure
10a and b). CXCL16 did not significantly modulate tubular
cell apoptosis either alone or in combination with TWEAK
(Figure 10a). CXCL16 induces proliferation in several cell
types, including mesangial cells.24,38–43 However, CXCL16 did
not modulate tubular cell proliferation alone and had a
nonsignificant effect on proliferation induced by TWEAK
(Figure 10b). By contrast, CXCL16 had a modest pro-
inflammatory effect on MCT cells and increased TWEAK-
induced expression of ICAM-1, MCP-1, and RANTES mRNA
(Figure 11).
DISCUSSION
The main finding of this study is that TWEAK modulates
CXCL16 expression in renal tubular cells in culture and
in vivo through activation of the NF-kB transcription factor,
and that CXCL16 cooperated with TWEAK in promoting an
inflammatory response in tubular cells. TWEAK neutraliza-
tion decreased CXCL16 expression and CD3-lymphocyte
infiltration in an experimental model of TII, suggesting the
relevance of the observation for kidney injury. In this regard,
tubular cell CXCL16 and Fn14 were also observed in human
renal TII.
There is evidence that CXCL16 participates in renal
disease. Blocking CXCL16 in the acute inflammatory phase
of experimental glomerulonephritis significantly attenuated
monocyte/macrophage infiltration and glomerular and
tubular injury.26,28 However, questions remain regarding
the regulation of CXCL16 expression and CXCL16 actions
on different intrinsic renal cells. CXCL16 is expressed by
immune cells such as dendritic cells, macrophages, B cells, T
cells, and on smooth muscle cells, hepatocytes, fibroblasts,
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Figure 4 | Localization of CXCL16 expression in experimental
tubulointerstitial inflammation (TII). Note tubular cell
localization of increased CXCL16 expression in mice with TII, when
compared with healthy control or mice with TII treated with anti-
TWEAK (tumor necrosis factor–like weak inducer of apoptosis).
Immunohistochemistry. Original magnification  400. Pictures
representative of eight animals per group.
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Figure 5 |TWEAK (tumor necrosis factor–like weak inducer
of apoptosis) neutralization decreases interstitial CD3+
lymphocytes in experimental tubulointerstitial inflammation
(TII). The increased number of interstitial lymphocytes stained
with anti-CD3 (arrows) in kidneys with TII was reduced by anti-
TWEAK antibody treatment. Original magnification  200.
Quantification as mean±SEM of eight animals per group.
*Po0.01 vs. control, **Po0.01 vs. TII.
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and endothelial cells.17,18,24,44–46 In addition, CXCL16 is
constitutively expressed in human mesangial cells, podocytes,
and tubular cells.23–25 Glomerular CXCL16 expression is
increased in human membranous nephropathy and in
experimental glomerular injury.25 In cultured glomerular
cells, CXCL16 is upregulated by TNF-a and IFN-g, but much
less is known about factors regulating CXCL16 expression in
renal tubular cells.23–25 IFN-g increased CXCL16 expression
in cultured primary thick ascending limb cells and early distal
tubular cells.23 However, there is evidence for differential
regulation of CXCL16 expression in different tubular
segments and in tubular injury of diverse etiology. Thus,
increased focally apical tubular CXCL16 expression was
observed in human allograft acute kidney injury.23 By
contrast, tubular CXCL16 was mostly negative in patients
with interstitial rejection and prominent interstitial T-cell
infiltration.23 The low CXCL16 expression in interstitial
rejection was attributed to increase CXCL16 shedding, and
remnant CXCL16 was located to the basolateral membrane.
In our experimental nephrotoxic TII model, both prominent
apical and basolateral CXCL16 expressions were noted. Thus,
other tubular cells, the interstitium, and the tubular lumen
were exposed to CXCL16 derived from tubular cells. In many
tubules both patterns did not overlap.
Leukocytes recruited by chemokines have a key role in
kidney tubulointerstitial tissue injury during acute kidney
injury and chronic kidney disease.47,48 CXCL16 has an
essential role in T-cell recruitment,23,25 and, recently,
TWEAKwas shown to induce kidney infiltration by T cells.34
We now demonstrate that TWEAK is a novel regulator of
CXCL16 expression in renal tubular epithelial cells in culture
and in vivo. TWEAK increased renal CXCL16 expression and
interstitial CD3-positive lymphocytes. TWEAK was also an
important stimulus for CXCL16 expression in an experi-
mental model of TII. In addition, neutralization of TWEAK
decreased CD3-lymphocyte infiltration. Although TWEAK
regulates the expression of several chemokines, we hypothe-
size that induction of CXCL16 expression in tubular cells may
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Figure 6 | Increased tubular fibroblast growth factor–
inducible 14 (Fn14) and CXCL16 expression is associated
with interstitial inflammatory infiltrates in human
tubulointerstitial inflammation (TII). (a) CXCL16
immunohistochemistry. CXCL16 is observed in renal tubules
(arrows) and in surrounding inflammatory infiltrates (arrowheads)
in a case of TII secondary to glomerular injury (rapidly progressive
glomerulonephritis), but not in minimal change disease (MCD).
(b) Fn14 immunohistochemistry. Fn14 is observed in the same renal
tubules (arrows) that were stained for CXCL16 in serial sections of
the same case of TII, but not in MCD. Original magnifications  200
and  400. Control for the technique is shown in Supplementary
Figure S3 online. Representative images of two patients with
MCD, and two with rapidly progressive glomerulonephritis.
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Figure 7 | Increased tubular fibroblast growth factor–inducible
14 (Fn14) and CXCL16 expression is associated with
interstitial inflammatory infiltrates in human acute
tubulointerstitial nephritis. (a) CXCL16 immunohistochemistry.
CXCL16 is observed in renal tubules (arrows) and in surrounding
inflammatory infiltrates (arrowheads). (b) Fn14
immunohistochemistry. Fn14 is observed in renal tubules (arrows)
of the same case. Original magnification  400.
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contribute to T-cell recruitment, as cell culture studies
suggest, and collaborate with TWEAK in promoting
inflammation. In this regard, in human interstitial inflam-
mation, Fn14-expressing tubules also expressed CXCL16 and
were surrounded by inflammatory infiltrates.
Interestingly, urinary CXCL16 excretion was increased in
patients and mice with lupus nephritis, and urinary TWEAK
was independently reported to be increased in these con-
ditions.27,49 In this regard, CXCL16 expression was increased
in glomeruli and tubules in lupus mice and in experimental
anti-glomerular basement membrane nephritis.26–28 Further-
more, elevated urinary CXCL16 was observed in transplant
patients with acute kidney dysfunction, in whom only tubu-
lar CXCL16 was upregulated, suggesting a tubular origin of
urinary CXCL16.23,27 TWEAK induction of CXCL16 expres-
sion in tubular cells could contribute to this observation.
CXCL16 has biological activities beyond leukocyte che-
motaxis. CXCL16 function may vary in a cell-specific
manner. CXCL16 induces proliferation in glial precursor
cells, myocardial fibroblasts, trophoblastic cells, endothelial
cells, aortic smooth muscle cells, and mesangial cells.24,38–42
However, in cancer cells, soluble CXCL16 induces proliferation
while transmembrane CXCL16 suppresses tumor pro-
liferation.43 Renal epithelial cell (podocyte and tubular cell)-
originated CXCL16 promotes chemotaxis of T cells and may
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Figure 8 | TWEAK (tumor necrosis factor–like weak inducer of
apoptosis) modulates CXCL16 expression in cultured renal
tubular cells. (a) MCT cells were stimulated with 100 ng/ml
TWEAK. Quantification of CXCL16 mRNA expression (real-time
quantitative reverse transcription-PCR). Expression level at 6 h
control was considered to be 100%. Mean±s.e.m. of three
independent experiments. *Po0.04 vs. control 6 h; #Po0.05 vs.
control 24 h. (b) MCT cells were pretreated for 1 h with 10 mmol/l
parthenolide and stimulated with TWEAK for 3 h. The nuclear
factor-kB inhibitor parthenolide prevented TWEAK-induced
CXCL16 upregulation. Mean±s.e.m. of three independent
experiments. *Po0.05 vs. vehicle; #Po0.05 vs. vehicleþ TWEAK.
Data were normalized with murine glyceraldehyde-3-phosphate
dehydrogenase mRNA. (c) MCT cells stimulated with TWEAK for
6 h or 24 h were analyzed for CXCL16 surface expression by flow
cytometry. Mean±s.e.m. of three independent experiments.
*Po0.03 vs. control. (d) NP-1 cells were treated with 100 ng/ml
TWEAK for 24 h. Soluble and cellular CXCL16 were quantified by
ELISA. Mean±s.e.m. of three independent experiments. *Po0.05
vs. control.
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Figure 9 |Confocal microscopy detection of CXCL16 and
CXCR6 expression in cultured tubular cells. Cells were
stimulated with 100 ng/ml TWEAK (tumor necrosis factor–like
weak inducer of apoptosis) or vehicle (control) for 24 h.
(a) Constitutive CXCR6 (green) and inducible CXCL16 (red)
expression in proximal tubular MCT cells. Original magnification
 40. (b) Constitutive CXCR6 and inducible CXCL16 expression in
proximal tubular MCT cells. Note the increased peripheral location
of CXCL16 following TWEAK with areas of overlap (yellow).
Original magnification  40, zoom 7. (c) Constitutive CXCR6 and
inducible CXCL16 expression in distal tubular NP1 cells. Original
magnification  40, zoom 7. Indirect immunofluorescence using
anti-CXCR6 with secondary Alexa Fluor 488–conjugated antibody
(green) and anti-CXCL16 antibodies with secondary Alexa Fluor
633–conjugated antibody (red). Nuclei were stained with
40-6-diamidino-2-phenylindole (blue). Images are representative
of three independent experiments.
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regulate the uptake of oxidized low-density lipoprotein,25
whereas mesangial cell CXCL16 promotes mesangial cell
proliferation.24 Despite this role regulating proliferation in
mesenchymal, endothelial, and tumor cells, CXCL16 did not
induce murine tubular epithelial cell proliferation or apoptosis,
either alone or in combination with TWEAK. TWEAK induces
proliferation in non-stressed renal tubular epithelium37 and
apoptosis in cells stressed by an inflammatory milieu composed
of TNF-a/IFN-g.4 Despite the lack of an effect of CXCL16 on
tubular cell proliferation, tubular cells expressed the CXCR6
receptor and CXCL16 had a proinflammatory effect on tubular
cells and increased TWEAK-induced gene expression of ICAM-
1, MCP-1, and RANTES. TWEAK promotes the expression of
chemokines through two distinct NF-kB pathways, the
canonical and the non-canonical pathway.12,50 The evidence
presented in this paper that TWEAK promotes CXCL16
expression through the canonical (parthenolide-sensitive) NF-
kB pathway extends the range of TWEAK-regulated chemo-
kines. In this regard, TWEAK-induced chemokines may behave
in a concerted manner to attract CD3 T cells and other
leukocytes to the tubulointerstitial space. We cannot exclude
that CXCL16 has additional actions on tubular cells, related to
its role as a scavenger receptor.17
In summary, we have identified TWEAK as a novel
regulator of CXCL16 expression in tubular cells in culture
and in vivo, thus further extending the range of inflammatory
mediators under the direct regulation of this master switch in
inflammation. In addition, we have identified direct proin-
flammatory actions of CXCL16 in renal tubular cells. This
information will be useful to define therapeutic strategies
targeting TWEAK and/or CXCL16 in kidney disease.
MATERIALS AND METHODS
Cells and reagents
MCT murine proximal tubular epithelial cells were cultured in
RPMI 1640, and NP-1 murine distal tubular epithelial cells were
cultured in DMEM supplemented with decomplemented fetal
bovine serum (10%), glutamine (2mmol/l), and penicillin/strepto-
mycin (100U/ml; LONZA, Verviers, Belgium) in 5% CO2 at
37 1C.4,51 Both cell lines were originated from the kidneys of SJL
mice in the University of Pennsylvania and obtained from Eric G
Neilson and Frank Strutz, respectively.52 Recombinant human
soluble TWEAK (Millipore, Massachusetts, MA) was used at
100 ng/ml, based on prior dose–response studies in these cells.3 Cell
culture and in vivo experiments suggest that human and murine
TWEAK have similar actions on murine renal cells.3,34,37,53 This is
not unexpected as the TWEAK and Fn14 amino-acid sequences are
remarkably conserved throughout evolution, and cross-reactivity
between human and mice has been documented biochemically and
in other cell systems.54 Recombinant mouse CXCL16 was obtained
from R&D Systems (Minneapolis, MN). The NF-kB inhibitor
parthenolide (Sigma, St Louis, MO) was used at 10mmol/l based on
previous dose–response studies in this system.3
Quantitative reverse transcription-PCR
Total RNA was isolated by using Trizol reagent (Invitrogen, Paisley,
UK). Complementary DNA was synthesized from 1 mg of total RNA
using High-Capacity complementary DNA Archive Kit, and real-
time PCR reactions were performed on the ABI Prism 7500
sequence-detection PCR system (Applied Biosystems, Foster City,
CA) using the DeltaDelta Ct method. Data were normalized with
murine glyceraldehyde-3-phosphate dehydrogenase or 18s eukar-
yotic ribosomal RNA expression. Primers were designed by Applied
Biosystems.
Flow cytometry analysis of CXCL16 expression
Cells were stimulated with TWEAK for 6 or 24 h. Adherent cells
were detached with 2.2mmol/l EDTA, 0.2% bovine serum albumin
in phosphate-buffered saline, and resuspended in 0.2% bovine
serum albumin/phosphate-buffered saline. In all, 5 104 cells were
stained with 1.5 mg/ml anti-CXCL16 antibody overnight at 4 1C,
followed by incubation with 1:100 fluorescein isothiocyanate
(FITC)-anti-goat IgG for 30min at 4 1C. Cells were then analyzed
on the FACScalibur (BD Bioscience, San Jose, CA). Dead cells and
debris were excluded from analysis by selective gating based on
anterior and right-angle scatter. At least 10,000 events were
collected for each sample, and data were displayed on a logarithmic
scale of increasing green-fluorescence intensity by CELL-QUEST
software.55
ELISA
Cells were stimulated with 100 ng/ml TWEAK for 24 h. CXCL16 was
measured in cell culture supernatants and cell lysates using a DuoSet
ELISA Development kit (R&D Systems), according to the manu-
facturer’s instructions.
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Immunostaining
Cells seeded in 24-well plates over glass coverslips were serum-
starved for 24 h and treated with TWEAK.25 Primary antibodies
were anti-mouse CXCL16 and monoclonal anti-mouse CXCR6
(R&D Systems). Bound antibodies were detected by Alexa Fluor 633
rabbit anti-goat and Alexa Fluor 488 donkey anti-rat secondary
antibodies, respectively (Invitrogen, San Diego, CA). Nuclei were
counterstained with 40-6-diamidino-2-phenylindole (Sigma, Dei-
senhofen, Germany). Cells were analyzed under a laser scanning
confocal microscope (Leica Microsystems, Wetzlar, Germany).
Flow cytometry assessment of cell death
Cells were cultured to subconfluence in 12-well plates and rested in
serum-free medium for 24 h before TWEAK addition. Apoptosis
was assessed by functional and morphological studies.37 Cell DNA
content was quantified by flow cytometry for assessment of cell cycle
and apoptosis.56,57 Adherent cells were pooled with spontaneously
detached cells, and stained in 100mg/ml propidium iodide, 0.05%
NP-40, 10 mg/ml RNAse A in phosphate-buffered saline, and
incubated at 4 1C for 41 h. This assay permeabilizes the cells and
thus it is not based on the known ability of propidium iodide to
enter dead cells. The percentage of apoptotic cells with decreased
DNA staining (A0) and of cells in the M and S phase of the cell cycle
was counted as previously described.4,37
Animal model
All procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals. C57/BL6 mice (12- to
14-week-old; IFFA-CREDO, Barcelona, Spain) were treated intra-
peritoneally with 70 mg per mouse parthenolide or its vehicle (0.05%
dimethyl sulfoxide) and 0.75 mg/mouse of TWEAK or saline vehicle
(200 ml 0.9% NaCl). Treatment and control groups (n¼ 6) were as
follows: (a) parthenolide followed by TWEAK, (b) vehicle (dimethyl
sulfoxide) followed by TWEAK, (c) parthenolide followed by saline,
and (d) vehicle (dimethyl sulfoxide) followed by saline. Parthenolide
was injected 24 h and TWEAK 4 h before killing. The dose of
TWEAK was calculated based on in vitro experiments for an
extracellular volume of 7.5ml per mouse, and was previously shown
to induce biological responses in kidneys.3 The dose of parthenolide
was established based on previous experience.3
Folic acid nephropathy is a classical model of kidney tubuloin-
terstitial injury and inflammation.3,29–31 C57/BL6 mice (12- to 14-
week-old) received a single intraperitoneal injection of folic acid
(Sigma) 300mg/kg in 0.3mol/l sodium bicarbonate or vehicle, and
mice were killed 72 h later, at the time of peak kidney injury. Mice
were dosed intraperitoneally with either 200mg of blocking anti-
TWEAK monoclonal antibody (clone P2D10, Biogen Idec) or
200 mg isotype IgG (mouseIgG2a, clone P1.17, Biogen Idec; n¼ 8
per group). Animals received the monoclonal antibody treatments 1
day before the folic acid injection and 2 days thereafter. The kidneys
were perfused in situ with cold saline before removal. One kidney
was snap-frozen in liquid nitrogen for RNA and protein studies and
the other fixed and paraffin embedded. Key findings were confirmed
in a second, independent experiment. Kidney sections were stained
with hematoxylin–eosin and Masson trichrome. Histopathological
changes indicating tubular cell injury (epithelial degradation that
includes apical desquamation, loss of brush border and vacuoliza-
tion in cytoplasm, tubular dilatation, hyaline or cellular casts,
tubulitis, mitosis, regenerative cells with increased volume of nuclei
and presence of nucleoli) and interstitial inflammation were assessed
by an experienced pathologist blinded to the origin of the samples.
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Figure 11 |CXCL16 modulates TWEAK (tumor necrosis
factor–like weak inducer of apoptosis)-induced tubular
inflammation. MCT cells were pretreated with 50 ng/ml CXCL16
for 1 h, and then stimulated with TWEAK for 6 h or 24 h. (a) ICAM-1
mRNA, *Po0.02 vs. control 6 h, **Po0.03 vs. control 24 h,
#Po0.05 vs. TWEAK 6 h, ##Po0.05 vs. TWEAK 24 h. (b) MCP-1
mRNA, *Po0.01 vs. control 6 h, **Po0.03 vs. control 24 h,
#Po0.05 vs. TWEAK 6 h. (c) RANTES mRNA, *Po0.01 vs. control
6 h, **Po0.03 vs. control 24 h, ##Po0.05 vs. TWEAK 24 h. Real-time
quantitative reverse transcription-PCR. Values for mRNA were
normalized to glyceraldehyde-3-phosphate dehydrogenase
expression. Expression level at 6 h control was considered to be
100%. Mean±s.e.m. of four independent experiments.
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Each of these variables was quantified semiquantitatively in a 0–3
scale to yield a global score (values 0–24) for each mouse as the sum
of the individual injury scores assessed in 10 randomly chosen fields
for each kidney (Supplemental Table S2 online).
Transcriptomics arrays
Transcriptomics arrays of kidney tissue were performed at Unidad
Geno´mica Moncloa, Fundacio´n Parque Cientı´fico de Madrid,
Madrid, Spain. Affymetrix microarray analysis was performed
following the manufacturer’s protocol. Image files were initially
obtained through Affymetrix GeneChip Command Console
Software. Subsequently, Robust Multichip Analysis was performed
using the Affymetrix Expression Console Software. Starting from
the normalized Robust Multichip Analysis, the Significance Analysis
of Microarrays was performed using the limma package (Babelo-
mics, http://www.babelomics.org), using a false discovery rate of 5%
to identify genes that were significantly differentially regulated
between the analyzed groups.
Immunohistochemistry
Immunohistochemistry was carried out as previously described on
paraffin-embedded 3-mm-thick tissue sections.25 For the animal
model, primary antibodies were goat anti-CXCL16 (R&D Systems)
and rabbit polyclonal anti-CD3 (Dako Diagnostics, Barcelona,
Spain). Dako REAL EnVision kit (Dako Diagnostics) was used
for CD3 staining. Sections were counterstained with Carazzi’s
hematoxylin. Negative controls included incubation with a nonspecific
immunoglobulin of the same isotype as the primary antibody.
Quantification of CD3-stained cells was made by a blinded observer
determining the total number of positive lymphocytes in 20 randomly
chosen fields ( 40) using the Image-Pro Plus Software (Media
cybernetics, Bethesda, MD). Some sections were also incubated with
the proximal tubule marker, FITC-Tetranogolobus lotus (diluted 1:33;
Sigma), or the collecting tubule marker, FITC-Dolichos biflorum
(diluted 1:33; Sigma), as described.57
Human kidney samples were obtained from 18 patients with TII
secondary to glomerular injury (12 membranous nephropathy, 2
rapidly progressive glomerulonephritis, 1 systemic lupus erythema-
tosus, 1 IgA nephropathy, 2 focal segmental glomerulosclerosis), 1
patient with acute interstitial nephritis, and 2 patients with minimal
change disease controls, 10 women and 11 men, aged 43±19 years,
serum creatinine 1.82±1.54mg/dl, and 24 h urinary protein
excretion 6.25±4.61 g. Formol tissue sections (4mm thick) were
dewaxed and rehydrated with distilled water. Antigen retrieval was
performed by incubating the tissue sections in sodium citrate (pH
6.0) for CXCL16 and Tris/EDTA (pH 9.0) for Fn14/TWEAK
receptor. Endogenous peroxidase was blocked with 3% H2O2 for
10min. The primary antibody was CXCL16 goat antibody (R&D
Systems) and anti-Fn14 mouse antibody (eBiosciences, San Diego,
CA) with the buffer containing 1% immunoglobulin-free bovine
serum albumin overnight at 4 1C. For CXCL16, the sections were
then incubated with biotinylated anti-goat antibody at 1:500 (Vector
Laboratories, Burlingame, CA) for 30min. After three rinses, they
were incubated with streptavidin peroxidase (Vector Laboratories)
for 30min. The slides were incubated with hematoxylin to
counterstain the sections and dehydrated and mounted with
Canadian balsam (Polysciences, Warrington, PA). For Fn14, the
sections were incubated with Vectastain PK 7200 detection Systems
(Vector Laboratories) and the red color was developed with
ImmPACT NovaRED substrate (Vector Laboratories). Negative
technique controls included incubation without a primary antibody.
The study protocol was approved by the local Ethics Committee and
informed consent was obtained.
Statistics
Statistical analysis was performed using the SPSS 11.0 statistical
software. Results are expressed as mean±s.e.m. Significance at the
Po0.05 level was assessed by Student’s t-test and nonparametric
Mann–Whitney U-test for two groups and analysis of variance for
three or more groups. Pearson correlation was used to assess
correlation between two continuous variables.
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